6 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 5 with minor changes only.
Recruitment opened
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 1 NCT07840612 Registry history of NCT07840612 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Aug 21, 2026 to Nov 24, 2026
EMD Serono Research & Development Institute, Inc.Phase 3 NCT03815643 Registry history of NCT03815643 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 52 → 65 participants
EMD Serono Research & Development Institute, Inc.Phase 1 NCT06641908 Registry history of NCT06641908 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 66 → 92 locations
EMD Serono Research & Development Institute, Inc.Phase 3 NCT07549412 Registry history of NCT07549412 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 36 → 57 locations
EMD Serono Research & Development Institute, Inc.Phase 3 NCT07355218 Registry history of NCT07355218 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 45 → 60 locations
EMD Serono Research & Development Institute, Inc.Phase 3 NCT07332481 Registry history of NCT07332481 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-09-25 | NCT07840287 A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With… | Phase 3 | Not Yet Recruiting |
| 2026-09-25 | NCT07840612 A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and… | Phase 1 | Recruiting |
| Phase 1 | 9 | |
| Phase 1/2 | 1 | |
| Phase 2 | 4 | |
| Phase 3 | 7 |
Lung Cancer (4) · Lupus (SLE) (4) · Non-Small Cell Lung Cancer (NSCLC) (4) · Colorectal Cancer (3) · Ovarian Cancer (3) · Gastric Cancer (2) · Bladder Cancer (1) · Breast Cancer (1) · Glioblastoma (1) · Glioma (1)